FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914897630> ?p ?o ?g. }

• W2914897630 endingPage "1606" @default.
• W2914897630 startingPage "1597" @default.
• W2914897630 abstract "Abstract The third-generation tyrosine kinase inhibitor (TKI) ponatinib has been associated with high rates of acute ischemic events. The pathophysiology responsible for these events is unknown. We hypothesized that ponatinib produces an endothelial angiopathy involving excessive endothelial-associated von Willebrand factor (VWF) and secondary platelet adhesion. In wild-type mice and ApoE−/− mice on a Western diet, ultrasound molecular imaging of the thoracic aorta for VWF A1-domain and glycoprotein-Ibα was performed to quantify endothelial-associated VWF and platelet adhesion. After treatment of wild-type mice for 7 days, aortic molecular signal for endothelial-associated VWF and platelet adhesion were five- to sixfold higher in ponatinib vs sham therapy (P &lt; .001), whereas dasatinib had no effect. In ApoE−/− mice, aortic VWF and platelet signals were two- to fourfold higher for ponatinib-treated compared with sham-treated mice (P &lt; .05) and were significantly higher than in treated wild-type mice (P &lt; .05). Platelet and VWF signals in ponatinib-treated mice were significantly reduced by N-acetylcysteine and completely eliminated by recombinant ADAMTS13. Ponatinib produced segmental left ventricular wall motion abnormalities in 33% of wild-type and 45% of ApoE−/− mice and corresponding patchy perfusion defects, yet coronary arteries were normal on angiography. Instead, a global microvascular angiopathy was detected by immunohistochemistry and by intravital microscopy observation of platelet aggregates and nets associated with endothelial cells and leukocytes. Our findings reveal a new form of vascular toxicity for the TKI ponatinib that involves VWF-mediated platelet adhesion and a secondary microvascular angiopathy that produces ischemic wall motion abnormalities. These processes can be mitigated by interventions known to reduce VWF multimer size." @default.
• W2914897630 created "2019-02-21" @default.
• W2914897630 creator A5000737891 @default.
• W2914897630 creator A5008830383 @default.
• W2914897630 creator A5019401898 @default.
• W2914897630 creator A5021549741 @default.
• W2914897630 creator A5030734396 @default.
• W2914897630 creator A5032806539 @default.
• W2914897630 creator A5033023115 @default.
• W2914897630 creator A5037936416 @default.
• W2914897630 creator A5038643808 @default.
• W2914897630 creator A5040785111 @default.
• W2914897630 creator A5050978437 @default.
• W2914897630 creator A5060472152 @default.
• W2914897630 creator A5081232337 @default.
• W2914897630 creator A5082229705 @default.
• W2914897630 creator A5082876895 @default.
• W2914897630 creator A5084109223 @default.
• W2914897630 creator A5087902228 @default.
• W2914897630 date "2019-04-04" @default.
• W2914897630 modified "2023-10-06" @default.
• W2914897630 title "Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib" @default.
• W2914897630 cites W1802526719 @default.
• W2914897630 cites W1814874339 @default.
• W2914897630 cites W1939978733 @default.
• W2914897630 cites W1964138924 @default.
• W2914897630 cites W1967796238 @default.
• W2914897630 cites W1978005077 @default.
• W2914897630 cites W1978549876 @default.
• W2914897630 cites W1986282241 @default.
• W2914897630 cites W1988734118 @default.
• W2914897630 cites W1995452044 @default.
• W2914897630 cites W1999364304 @default.
• W2914897630 cites W2011768933 @default.
• W2914897630 cites W2021665232 @default.
• W2914897630 cites W2028031291 @default.
• W2914897630 cites W2033417194 @default.
• W2914897630 cites W2047985610 @default.
• W2914897630 cites W2055603146 @default.
• W2914897630 cites W2055923362 @default.
• W2914897630 cites W2072625253 @default.
• W2914897630 cites W2085540799 @default.
• W2914897630 cites W2095215050 @default.
• W2914897630 cites W2096190607 @default.
• W2914897630 cites W2100303262 @default.
• W2914897630 cites W2101096780 @default.
• W2914897630 cites W2104694028 @default.
• W2914897630 cites W2110648386 @default.
• W2914897630 cites W2118332313 @default.
• W2914897630 cites W2119250965 @default.
• W2914897630 cites W2125542444 @default.
• W2914897630 cites W2144398438 @default.
• W2914897630 cites W2156749399 @default.
• W2914897630 cites W2162118609 @default.
• W2914897630 cites W2164796241 @default.
• W2914897630 cites W2167279371 @default.
• W2914897630 cites W2401908067 @default.
• W2914897630 cites W2741216563 @default.
• W2914897630 cites W2763370961 @default.
• W2914897630 cites W2775819627 @default.
• W2914897630 cites W2790692615 @default.
• W2914897630 cites W2804799628 @default.
• W2914897630 cites W2888189447 @default.
• W2914897630 cites W4211092601 @default.
• W2914897630 cites W42623565 @default.
• W2914897630 doi "https://doi.org/10.1182/blood-2018-10-881557" @default.
• W2914897630 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6450432" @default.
• W2914897630 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30692122" @default.
• W2914897630 hasPublicationYear "2019" @default.
• W2914897630 type Work @default.
• W2914897630 sameAs 2914897630 @default.
• W2914897630 citedByCount "57" @default.
• W2914897630 countsByYear W29148976302019 @default.
• W2914897630 countsByYear W29148976302020 @default.
• W2914897630 countsByYear W29148976302021 @default.
• W2914897630 countsByYear W29148976302022 @default.
• W2914897630 countsByYear W29148976302023 @default.
• W2914897630 crossrefType "journal-article" @default.
• W2914897630 hasAuthorship W2914897630A5000737891 @default.
• W2914897630 hasAuthorship W2914897630A5008830383 @default.
• W2914897630 hasAuthorship W2914897630A5019401898 @default.
• W2914897630 hasAuthorship W2914897630A5021549741 @default.
• W2914897630 hasAuthorship W2914897630A5030734396 @default.
• W2914897630 hasAuthorship W2914897630A5032806539 @default.
• W2914897630 hasAuthorship W2914897630A5033023115 @default.
• W2914897630 hasAuthorship W2914897630A5037936416 @default.
• W2914897630 hasAuthorship W2914897630A5038643808 @default.
• W2914897630 hasAuthorship W2914897630A5040785111 @default.
• W2914897630 hasAuthorship W2914897630A5050978437 @default.
• W2914897630 hasAuthorship W2914897630A5060472152 @default.
• W2914897630 hasAuthorship W2914897630A5081232337 @default.
• W2914897630 hasAuthorship W2914897630A5082229705 @default.
• W2914897630 hasAuthorship W2914897630A5082876895 @default.
• W2914897630 hasAuthorship W2914897630A5084109223 @default.
• W2914897630 hasAuthorship W2914897630A5087902228 @default.
• W2914897630 hasBestOaLocation W29148976301 @default.
• W2914897630 hasConcept C126322002 @default.
• W2914897630 hasConcept C134018914 @default.

• next